Intellia Therapeutics Inc NTLA:NASDAQ

Last Price$106.92NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/01/21

Today's Change-8.09(7.03%)
Bid (Size)$106.97 (3)
Ask (Size)$111.25 (1)
Day Low / High$106.90 - 117.70
Volume958.9 K

Intellia Therapeutics Gets New Zealand Ok to Start Phase 1/2 Clinical Trial of Hereditary Angioedema Treatment

8:08AM ET 10/06/2021 MT Newswires
Intellia Therapeutics (NTLA) said Wednesday it has received approval from the New Zealand Medicines and Medical Devices Safety Authority to start a phase 1/2 study on NTLA-2002 for the treatment of hereditary angioedema.

The clinical-stage company said the phase 1/2 study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-2002, adding that it is on track to start patient enrollment by the end of this year.

NTLA-2002 is a single-dose genome editing therapeutic candidate designed to prevent hereditary angioedema attacks.

Hereditary angioedema is a rare, genetic disorder causing severe and unpredictable inflammatory attacks on organs and tissues.

Shares of the company inched 0.5% higher in recent pre-bell trading on Wednesday.

Price: 130.00, Change: +0.24, Percent Change: